Key Points
- Director Bruce Cozadd sold 6,000 Jazz Pharmaceuticals shares for approximately $1.52 million at an average price of $252.98 under a pre-arranged Rule 10b5-1 plan, reducing his ownership by 1.64%.
- Jazz reported quarterly revenue of $1.21 billion, up 15.5% year over year and above estimates, but adjusted EPS of $5.71 missed the $6.18 consensus forecast.
- Analysts maintain a favorable outlook, with the stock carrying a “Moderate Buy” consensus rating and a $272.74 average price target; institutional investors own approximately 89.14% of outstanding shares.
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Get Free Report) Director Bruce Cozadd sold 6,000 shares of Jazz Pharmaceuticals stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $252.98, for a total transaction of $1,517,880.00. Following the transaction, the director directly owned 360,682 shares of the company's stock, valued at approximately $91,245,332.36. This trade represents a 1.64% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Jazz Pharmaceuticals Price Performance
Shares of JAZZ opened at $261.57 on Thursday. The firm has a market capitalization of $16.98 billion, a PE ratio of 18.04, a PEG ratio of 0.23 and a beta of 0.32. The company's 50-day moving average is $240.46 and its 200-day moving average is $208.57. Jazz Pharmaceuticals PLC has a fifty-two week low of $105.00 and a fifty-two week high of $265.05. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.78 and a quick ratio of 1.85.
Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last posted its earnings results on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $6.18 by ($0.47). The company had revenue of $1.21 billion for the quarter, compared to analyst estimates of $1.11 billion. Jazz Pharmaceuticals had a return on equity of 33.97% and a net margin of 20.45%.The business's quarterly revenue was up 15.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($8.25) EPS. Equities analysts forecast that Jazz Pharmaceuticals PLC will post 21.9 EPS for the current year.
Wall Street Analysts Forecast Growth
Several research firms have recently commented on JAZZ. Wells Fargo & Company upped their target price on Jazz Pharmaceuticals from $285.00 to $300.00 and gave the company an "overweight" rating in a research report on Tuesday. Leerink Partners lifted their price target on Jazz Pharmaceuticals from $215.00 to $225.00 and gave the stock an "outperform" rating in a report on Wednesday, April 22nd. Royal Bank Of Canada boosted their price target on Jazz Pharmaceuticals from $195.00 to $258.00 and gave the company an "outperform" rating in a research note on Wednesday, May 6th. Truist Financial set a $264.00 price objective on Jazz Pharmaceuticals and gave the company a "buy" rating in a report on Tuesday. Finally, Bank of America increased their price objective on Jazz Pharmaceuticals from $281.00 to $307.00 and gave the stock a "buy" rating in a research report on Wednesday, June 10th. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $272.74.
Get Our Latest Stock Analysis on JAZZ
Institutional Investors Weigh In On Jazz Pharmaceuticals
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Capital World Investors grew its position in Jazz Pharmaceuticals by 4.4% during the fourth quarter. Capital World Investors now owns 2,666,602 shares of the specialty pharmaceutical company's stock worth $453,322,000 after buying an additional 111,735 shares in the last quarter. Ameriprise Financial Inc. raised its holdings in Jazz Pharmaceuticals by 11.4% in the 2nd quarter. Ameriprise Financial Inc. now owns 1,867,399 shares of the specialty pharmaceutical company's stock valued at $198,159,000 after acquiring an additional 191,637 shares in the last quarter. Franklin Resources Inc. raised its holdings in Jazz Pharmaceuticals by 164.0% in the 4th quarter. Franklin Resources Inc. now owns 1,818,911 shares of the specialty pharmaceutical company's stock valued at $309,215,000 after acquiring an additional 1,129,995 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of Jazz Pharmaceuticals by 44.5% during the 1st quarter. Bank of New York Mellon Corp now owns 1,679,371 shares of the specialty pharmaceutical company's stock valued at $317,485,000 after acquiring an additional 517,514 shares during the period. Finally, Fuller & Thaler Asset Management Inc. lifted its position in shares of Jazz Pharmaceuticals by 3.1% during the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 1,677,132 shares of the specialty pharmaceutical company's stock valued at $285,113,000 after acquiring an additional 50,996 shares during the period. 89.14% of the stock is currently owned by institutional investors and hedge funds.
Jazz Pharmaceuticals News Summary
Here are the key news stories impacting Jazz Pharmaceuticals this week:
- Positive Sentiment: Jazz reported second-quarter revenue of $1.21 billion, ahead of the $1.11 billion consensus estimate and up 15.5% year over year. Management raised its 2026 revenue forecast to $4.60 billion-$4.75 billion, citing strength in its oncology and neuroscience businesses. JAZZ Q2 Earnings Miss, Sales Beat, Stock Jumps on Raised 2026 View
- Positive Sentiment: The company’s oxybate franchise, led by Xywav, continues to grow at a double-digit rate despite the launch of generic Xyrem, easing concerns about generic competition and supporting the improved guidance. Jazz Pharmaceuticals' Re-Rating Story Has Legs
- Positive Sentiment: Multiple analysts raised their price targets following the results. Needham lifted its target to $292 and maintained a buy rating, while Morgan Stanley and Robert W. Baird raised targets to $280 with overweight and outperform ratings, respectively. JPMorgan also raised its target to $276 and maintained overweight ratings. Needham Raises Jazz Pharmaceuticals Price Target
- Positive Sentiment: Investors are also watching zanidatamab, marketed as Ziihera. A potential first-line gastroesophageal adenocarcinoma approval, with an FDA decision expected August 25, could create a significant new revenue stream and accelerate growth. Jazz Forecasts 2026 Revenue Ahead of Zanidatamab FDA Decision
- Neutral Sentiment: Second-quarter adjusted EPS was $5.71, below the $6.18 consensus estimate. The revenue beat and raised outlook outweighed the earnings miss in the market’s initial reaction, but profitability remains an area to monitor.
- Negative Sentiment: Jazz said it will withdraw Zepzelca from the FDA’s accelerated-approval pathway for second-line small-cell lung cancer, removing a potential regulatory catalyst and highlighting pressure on that product. Jazz to Withdraw Zepzelca FDA Application
- Negative Sentiment: Director Bruce C. Cozadd sold 6,000 shares worth approximately $1.52 million under a pre-arranged Rule 10b5-1 plan. Because the sale reduced his holdings by only 1.64% and was planned in advance, it is a limited negative signal rather than a clear change in insider conviction. Jazz Pharmaceuticals Insider Transaction Filing
About Jazz Pharmaceuticals
(
Get Free Report)
Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company's research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz's product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.
Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
